Mode
Text Size
Log in / Sign up
N/A N=143 Randomized Single-blind

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

Cardiovascular Disease

Enrolled (actual)
143
Serious AEs
Results posted
Apr 2012
Primary outcome: Primary: Patient-reported Adherence to Triple Therapy (Aspirin/Antiplatelet; Beta Blocker; and Statin) at 6 Months — 91; 94 percentage of participants — p=.50

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
oral education & written tips for remembering medications (Behavioral); pill box (Device); pocket medication card (Device); sharing information with community pharmacist (Behavioral); Medication use evaluations by community pharmacist (Behavioral); informing physician if patient has stopped a medication (Behavioral); Routine discharge counseling (Behavioral); Letter to physician/discharge summary (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Mar 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Patient-reported Adherence to Triple Therapy (Aspirin/Antiplatelet; Beta Blocker; and Statin) at 6 Months
91; 94 .50
SECONDARY
Percent of Patients Adherent to Beta-blocker and Statin Via Refill Records
53; 38 =0.11
SECONDARY
Percent of Patients Adherent to Beta-blocker Via Refill Records
71; 49 0.03 sig
SECONDARY
Percent of Patients Adherent to Statin Via Refill Records
58; 49 0.34
SECONDARY
Death in Intervention Patients Compared to Usual Care
1; 2

Summary

The purpose of this study is to evaluate the effectiveness of a program to help patients with heart disease stay on their heart medications.

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Utilize a pharmacy in Durham, Robeson, Person, Granville, or Vance County, NC
  • Have coronary artery disease (CAD) documented in the medical record by one of the following:
  • A diagnosis of unstable angina or acute myocardial infarction (ST segment elevation or non-ST segment elevation myocardial infarction)
  • A cardiac catheterization demonstrating CAD greater than or equal to 50 narrowing of artery)
  • Prior angioplasty
  • Prior coronary artery stent
  • Prior coronary artery bypass graft surgery (CABG)
  • Plan to have their prescription medications filled and refilled by one of the participating pharmacies
  • Prescribed aspirin or another antiplatelet, a beta-blocker and statin agent (referred to as triple therapy for this study) at discharge. If a patient has a true contraindication to any of the three medication groups in triple therapy, they will still be eligible for the study

Exclusion Criteria

  • Providers predict an anticipated hospital stay of less than 48 hours
  • Patient plans to use a pharmacy outside of Durham, Robeson, Person, Granville, or Vance County, NC
  • Patient is unable to give consent (cognitively impaired, does not speak English, or has altered mental status)
  • Patient transferred to Cardiothoracic Surgery service for CABG
  • Patient has terminal condition and may not survive until 6-month follow-up
  • Patient lives in a correctional or long-term care facility
  • Patient will be unable to participate in follow-up phone call (hearing impaired without caregiver who can help or does not have a phone)
  • Patient is a known participant in the Duke Heart Failure Program
  • Patient does not agree to use only the one Durham, Robeson, Person, Granville, or Vance County pharmacy throughout the study period
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00323258). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search